The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Dietary and pharmacological treatment of abdominal pain in IBS
Open accessAbstract
This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), μ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity. The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1 Classes of pharmacological agents for visceral pain Antidepressants (tricyclic agents, selective serotonin reuptake inhibitors) Peppermint oil 5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron) Non-absorbed antibiotic (rifaximin) Secretagogues (lubiprostone, linaclotide) μ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline) Histamine H1 receptor antagonist (ebastine) Neurokinin-2 receptor antagonist (ibodutant) GABAergic agents (gabapentin and pregabalin)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
Diets that differ in their FODMAP content alter the colonic luminal microenvironment
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015) · Gut · doi:10.1136/gutjnl-2014-307264 · Cited by 681
Böhn, L., Störsrud, S., Törnblom, H., Bengtsson, U., & Simrén, M. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.105 · Cited by 655
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Kim, H. J., Camilleri, M., Mckinzie, S., Lempke, M. B., Burton, D. D., Thomforde, G. M., & Zinsmeister, A. R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01543.x · Cited by 468
Self-citationTillisch, K., Mayer, E. A., & Labus, J. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.07.053 · Cited by 412
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.148 · Cited by 405
Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400
Self-citation
Cited by
Drewes, A. M., Olesen, A. E., Farmer, A. D., Szigethy, E., Rebours, V., & Olesen, S. S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0135-7 · Cited by 272
Bosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920928984 · Cited by 221
Gastrointestinal medication burden among persons with the Ehlers‐Danlos syndromes
Dhingra, R., Bascom, R., Thompson, E., Francomano, C. A., & Schubart, J. R. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14077 · Cited by 7
Metadata
- Authors
- Camilleri, M., & Boeckxstaens, G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2017-02-23
- Volume
- 66
- Issue
- 5
- Pages
- 966-974
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2590344642
- Cited by
- 158
- References
- 29
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dietary and pharmacological treatment of abdominal pain in IBS. https://app.cochat.ai/papers/10.1136/gutjnl-2016-313425
- The paper
- Camilleri, M., & Boeckxstaens, G. (2017). Dietary and pharmacological treatment of abdominal pain in IBS. Gut. https://doi.org/10.1136/gutjnl-2016-313425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.